Labrosse R, Barmettler S, Derfalvi B, et al. - Researchers performed a multi-center, retrospective cohort study to determine the prevalence, risk factors and clinical significance of hypogammaglobulinemia following rituximab (RTX) therapy in children. Clinical and immunological data were extracted from pediatric patients who received RTX. There were 207 patients (median age 12.0 years) in the cohort. Hypogammaglobulinemia post-RTX is a common diagnosis in the pediatric population. Low IgG levels are linked to an increase in serious infections, and underlying PIDs are relatively common in children receiving RTX, emphasizing the significance of immunologic monitoring both before and after RTX therapy.